To remove circulating harmful small biochemical(s)/substrates causing/deteriorating certain chronic disease, therapeutic enzyme(s) delivered via vein injection/infusion suffer(s) from immunoresponse after repeated administration at proper intervals for a long time and short half-lives since delivery. Accordingly, a novel, generally-applicable extracorporeal delivery of a therapeutic enzyme is proposed, by refitting a conventional hemodialysis device bearing a dialyzer, two pumps and connecting tubes, to build a routine extracorporeal blood circuit but a minimal dialysate circuit closed to circulate the therapeutic enzyme in dialysate. A special quantitative index was derived to reflect pharmacological action and thus pharmacodynamics of the delivered enzyme. With hyperuricemic blood in vitro and hyperuricemic geese, a native uricase via extracorporeal delivery was active in the dialysate for periods much longer than that in vivo through vein injection, and exhibited the expected pharmacodynamics to remove uric acid in hyperuricemic blood in vitro and multiple forms of uric acid in hyperuricemic geese. Therefore, the extracorporeal delivery approach of therapeutic enzymes was effective to remove unwanted circulating small biochemical(s)/substrates, and was expected to avoid immunogenicity problems of therapeutic enzymes after repeated administration at proper intervals for a long time due to no contacts with macromolecules and cells in the body.
Digital Object Identifier (DOI)
The work was supported by National Natural Science Foundation of China (nos 30672139, 21402108 and 31570862), the Sciences and Technology Commission of Yuzhong District of Chongqing (no. 20130135), the Education Ministry of China (no. 20125503110007) and Chongqing Sciences and Technology Commission (CSTC2011BA5039).
Zhang, Chun; Pu, Jun; Yang, Xiaolan; Feng, Tao; Liu, Fang; Wang, Deqiang; Hu, Xiaolei; Gao, Ang; Liu, Hongbo; Zhan, Chang-Guo; and Liao, Fei, "Extracorporeal Delivery of a Therapeutic Enzyme" (2016). Molecular Modeling and Biopharmaceutical Center Faculty Publications. 5.
Supplementary Information: Supplementary Note S1-S2
srep30888-s2.xls (341 kB)
Supplementary Data S1
srep30888-s3.xls (564 kB)
Supplementary Data S2
srep30888-s4.xls (579 kB)
Supplementary Data S3
srep30888-s5.xls (63 kB)
Supplementary Data S4
srep30888-s6.xls (255 kB)
Supplementary Data S5